Mita Manna
YOU?
Author Swipe
View article: Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers
Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers Open
The adjuvant treatment landscape for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer (EBC) is rapidly evolving, with a diverse range of therapeutic options—including endocrine …
View article: Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study
Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study Open
PURPOSE Breast cancer is uncommon in adolescent and young adult (AYA) women, accounting for approximately 1.8% of all breast cancers. There is a risk of delayed diagnosis of breast cancer among AYA women, especially among those residing in…
View article: Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach
Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach Open
Breast cancer remains the second leading cause of cancer-related death among women in Canada. In early-stage disease, the purpose of adjuvant therapies following surgical resection is to reduce the risk of recurrence. The advent of adjuvan…
View article: Use of landiolol for acute heart rate management in critically ill cardiac patients: a retrospective single-center experience
Use of landiolol for acute heart rate management in critically ill cardiac patients: a retrospective single-center experience Open
Background Landiolol, an ultra-selective beta-1-blocker with rapid onset and short half-life, is increasingly used for heart rate control in critically ill patients. Existing studies primarily focus on on its use in septic shock and post-c…
View article: Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada
Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada Open
The explosion in biomarker testing over the past two decades continues to transform cancer care in Canada and around the world. Precision medicine is supported by identifying actionable mutations that direct therapeutic choices, thus impro…
View article: Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer Open
The accurate staging of breast cancer is fundamental for guiding treatment decisions and predicting patient outcomes. However, there can be considerable variation in routine clinical practice based on individual interpretation of guideline…
View article: Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting Open
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies tha…
View article: Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer Open
Sacituzumab Govitecan (SG) is an antibody-drug conjugate (ADC) comprised of an anti-Trop-2 IgG1 molecule conjugated to SN-38, the active metabolite of irinotecan, via a pH-sensitive hydrolysable linker. As a result of recent Canadian fundi…
View article: An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management
An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management Open
Managing breast cancer in premenopausal women poses unique challenges due to its considerable effect on both morbidity and mortality. Goserelin, a gonadotropin-releasing hormone agonist, has emerged among the various modalities as a prefer…
View article: 280P Outcomes of women with early-stage triple-negative breast cancer (TNBC) in connection with age and other socio-demographic factors: A population based cohort study
280P Outcomes of women with early-stage triple-negative breast cancer (TNBC) in connection with age and other socio-demographic factors: A population based cohort study Open
TNBC is associated with a high risk of local and distant recurrence and is diagnosed at a relatively younger age. There is a paucity of trials focusing on women ≥70 yrs with TNBC. We aimed to determine the outcomes of women with TNBC in re…
View article: Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement Open
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. The…
View article: Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement Open
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. The…
View article: Outcomes of Rural Men with Breast Cancer: A Multicenter Population Based Retrospective Cohort Study
Outcomes of Rural Men with Breast Cancer: A Multicenter Population Based Retrospective Cohort Study Open
Background: Breast cancer is rare in men. This population-based study aimed to determine outcomes of male breast cancer in relation to residence and other variables. Methods: In this retrospective cohort study, men diagnosed with breast ca…
View article: Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience
Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience Open
Introduction: Fulvestrant has demonstrated efficacy in hormone receptor positive (HR+) metastatic breast cancer (mBC), both in first-and second-line settings. In clinical practice, however, fulvestrant has been used as a later-line therapy…
View article: Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience
Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience Open
Introduction: Fulvestrant has demonstrated efficacy in hormone receptor positive (HR+) metastatic breast cancer (mBC), both in first- and second-line settings. In clinical practice, however, fulvestrant has been used as a later-line therap…
View article: Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer Open
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to end…
View article: 263 Radiomics of the primary tumour as a tool to improve 18F-FDG-PET sensitivity in detecting nodal metastases in women with apparent early endometrial cancer
263 Radiomics of the primary tumour as a tool to improve 18F-FDG-PET sensitivity in detecting nodal metastases in women with apparent early endometrial cancer Open
Objectives In this study we investigated the role of radiomic applied in women with endometrial cancer underwent 18F-FDG PET scan, to evaluate if imaging features computed on the primary tumor could improve sensitivity in detection of lymp…
View article: Use of Obinutuzumab for B-cell Malignancies
Use of Obinutuzumab for B-cell Malignancies Open
We analysed data for the use of obinutuzumab in the treatment of CD20-positive lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL). Marked progress in the outcomes of B-cell NHL came w…